Skip to the content

Daniel Har, M.D.

Medical Degree

Albert Einstein College of Medicine

Board Certification

Internal Medicine
Pediatric and Adult Allergy & Immunology

Residency

University of Texas Southwestern

Fellowship

University of Texas Southwestern

Professional Associations
  • Texas Allergy, Asthma, and Immunology Society
  • American Academy of Allergy, Asthma & Immunology
  • American College of Allergy, Asthma & Immunology
  • American Board of Internal Medicine
  • Texas Medical Association
  • Dallas County Medical Society
Hospital Affiliations

University of Texas Southwestern
Clinical Instructor

Baylor Medical Center of Frisco
Medical Staff

Publications

Har D, Lee M. Systemic Reaction Rates with Omalizumab, Subcutaneous Immunotherapy, and Combination Therapy in Children with Allergic Asthma. In Press

Parrish C1, Har D1, Bird JA. Current Status of Potential Therapies for IgE-Mediated Food Allergy. Curr Allergy Asthma Rep. 2018 Feb 22;18(3):18.

Har D, Bird JA. Efficacy and Safety of Benralizumab for Patients With Severe Asthma Uncontrolled With High-Dosage Inhaled Corticosteroids and Long-acting β2-agonists (SIROCCO): A Randomised, Multicentre, Placebo-Controlled Phase 3 Trial. Pediatrics Dec 2017, 140 (Supplement 3) S224-S225.

Har D, Solensky R. Penicillin and Beta Lactam Hypersensitivity. Immunol Allergy Clin North Am. 2017 Nov;37(4):643-662.

Kim JK1, Har D1, Brown LS2, Khan DA3. Recurrence of Chronic Urticaria: Incidence and Associated Factors. J Allergy Clin Immunol Pract. 2017 Sep 6. pii: S2213-2198(17)30537-8.

Har D, Patel S, Khan DA. Outcomes of Using Omalizumab for More than 1 Year in Refractory Chronic Urticaria. Ann Allergy Asthma Immunol. 2015 Aug;115(2):126-9.

Our goal is to provide exceptional care to you and your family.